SCHEMBL12373565

SCHEMBL12373565

CCn1c(C(C)NS(=O)(=O)c2cc(F)ccc2C)cnc1Oc1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.40
BRD1 O95696 1/20 0.40
BRPF1 P55201 1/20 0.40
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
S1PR1 P21453 3/20 0.35
S1PR3 Q99500 1/20 0.35
CASP1 P29466 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEP1B Q16820 1/20 0.35
P2RX3 P56373 2/20 0.34
NR3C1 P04150 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12373611 0.93 KAT6A (0.40) TP53MAPTMEN1KMT2AS1PR1
SCHEMBL12373677 0.93 NR3C1 (0.36) TP53MAPTMEN1KMT2AS1PR1
SCHEMBL12373527 0.92 ALDH1A1 (0.43) ALDH1A1CYP2C19MEN1KMT2AHTT
SCHEMBL12373584 0.91 KAT6A (0.40) TP53MAPTS1PR1S1PR3HTT
SCHEMBL12373668 0.89 KMT2A (0.36) TP53MAPTMEN1KMT2AS1PR1
SCHEMBL12373589 0.89 S1PR1 (0.40) TP53MAPTALDH1A1S1PR1S1PR3
SCHEMBL12373694 0.88 S1PR1 (0.39) TP53MAPTMEN1KMT2AS1PR1
SCHEMBL12373692 0.87 S1PR1 (0.40) S1PR1S1PR3P2RX3
SCHEMBL12373639 0.87 S1PR1 (0.38) ALDH1A1MEN1KMT2AS1PR1S1PR3
SCHEMBL12373520 0.87 CASP1 (0.39) TRIM24BRD1BRPF1MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE S1PR1, S1PR3, S1PR2 TRIM24 4144/4885BRD1 1843/4885BRPF1 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.